Yamashita Hideomi, Nakagawa Keiichi, Tago Masao, Nakamura Naoki, Shiraishi Kenshiro, Mafune Ken-ichi, Kaminishi Michio, Ohtomo Kuni
Department of Radiology, University of Tokyo Hospital, Japan.
Radiat Med. 2006 Jan;24(1):65-71. doi: 10.1007/BF02489991.
To evaluate the treatment outcome of preoperative neoadjuvant radiotherapy combined with chemotherapy (CTx) for 17 esophageal cancer patients.
Between 1992 and 2004, patients with locally advanced esophageal cancer (stage III or IV) before curative-intent surgery received radiotherapy (RT) combined with CTx (Cisplatin: 75 mg/m2, bolus infusion, and 5-fluorouracil (5-FU): 1,000 mg/m2/24 h, continuous infusion for 4 days) at a median total dose of 30 Gy (n=17).
The median survival period was 13.8 months. The overall survival rates at 1, 2, and 3 years were 75%, 40%, and 20%, respectively. According to univariate analysis, no factor of worse prognosis was found. Pathological markedly (Grade 3) or moderately (Grade 2) effects were observed in 4 patients (24%) and 8 patients (47%), respectively.
These results indicate that, although this regimen was effective in terms of pathological effect, it is unclear whether it made a contribution to the improvement of survival
评估术前新辅助放疗联合化疗（CTx）对17例食管癌患者的治疗效果。
1992年至2004年间，拟行根治性手术的局部晚期食管癌（III期或IV期）患者在术前接受放疗（RT）联合CTx（顺铂：75mg/m²，静脉推注，5-氟尿嘧啶（5-FU）：1000mg/m²/24h，持续输注4天），中位总剂量为30Gy（n = 17）。
中位生存期为13.8个月。1年、2年和3年的总生存率分别为75%、40%和20%。单因素分析未发现预后较差的因素。分别有4例患者（24%）和8例患者（47%）观察到病理上显著（3级）或中度（2级）疗效。
这些结果表明，尽管该方案在病理疗效方面有效，但尚不清楚其是否有助于提高生存率。
